

PROFESSIONAL CURRICULA VITAE OF MEMBERS OF THE MANAGEMENT BOARD AND THE SUPERVISORY BOARD OF BIOTON S.A.

Management Board

Robert Neymann - President of the Management Board

In the years 1982-1987, Mr. Robert Neymann studied at the Warsaw School of Economics (major subject: Finance).

Mr. Robert Neymann worked successively:

- 1987 to 1990, at OMC Poll Ltd. as a financial comptroller at the Controlling Department; – Sales Manager for the Blendax product line in Poland;
- 1990 to 1991, at Procter & Gamble Polska as National Key Account Manager;
- 1991 to 1993, at Procter & Gamble Polska as Unit Sales Manager (Northern Poland);
- 1993 to 1994, at Procter & Gamble Polska as Trade Marketing Manager;
- 1994 to 1996, at Procter & Gamble Polska as District Sales Manager (Central and Northern Poland);
- 1996 to 1999, at Procter & Gamble Central and Eastern Europe as Distributor Operations Manager C&EE;
- 1999 to 2000, at Procter & Gamble Western Europe as Laundry Additives Customer Business Development Manager Western Europe;
- 2001 to 2005, at Herbapol Lublin S.A. as Vice President of the Management Board for Commercial Affairs;
- 2005 to 2007, at Polsnack Sp. z o.o. as President of the Management Board;
- 2009 to 2011, at Harper Trade Sp. z o.o. as President of the Management Board;
- 2007 to 2017, at Harper Hygienics S.A. as President of the Management Board.

Adam Polonek - Member of the Management Board

Mr. Adam Polonek is a graduate of the University of Economics in Katowice. He has extensive knowledge and experience in managing finances of companies and capital market. Since 2006 he has been an employee of BIOTON S.A. where he was holding first the position of deputy Chief Financial Officer and then the position of Chief Financial Officer. During this time he had the opportunity to improve his knowledge and competence in managing finances of the company, debt funding, development projects and restructuring transactions. Is also performing shareholding supervision in the subsidiaries of BIOTON S.A. In 2000-2006 was employed at CAIB Financial Advisers (at present UniCredit CAIB Poland), holding the positions from an analyst to a deputy director, where he was dealing with consultancy in mergers and acquisitions, evaluation of enterprises and optimization of financing structures. He has participated in a number of training within the scope of international accounting standards, evaluation of enterprises and project management. He is fluent in English. Since

20 December 2011 he has been holding the function of a Member of the Management Board of BIOTON S.A.

Supervisory Board

Mr. Jubo Liu – President of the Supervisory Board

Mr. Jubo Liu is the founder and has served as the CEO of Cogenes Biotechnology Incorporation (focused on in vitro diagnosis R&D, manufacturing and marketing) since August 2011 and served as the CEO of NovoTek Pharmaceuticals Limited (Hong Kong) and NovoTek Therapeutics Inc (Beijing) (international platform to globalize healthcare products both from within and outside of China) from August 2009 to March 2018. From April 2008 to July 2009 he was the China Chief Representative of Immtech Pharmaceuticals Inc. (US New York) (establishing Chinese activity infrastructure and investment plans). From November 2007 to April 2008, he acted as a Clinical Trial Liaison with US-based Pharmaceuticals Inc. (US New York) (carrying out global clinical trial operation in China). From October 2006 to November 2007 he was a scientist at Boston Vertex Pharmaceuticals Inc. (formulation and drug delivery). From July of 2005 to January of 2007 he was as a cofounder and served as the Director of Business Development of JCS Biopolytech Incorporation (modified biopolymer R&D and marketing used for drug delivery and nanotechnology). From August 1997 to February 2001, he served as the Director of Marketing and Regulatory Affairs for Huayuanlong Medicinal Technology Development Co. Ltd. of Beijing, China. Mr. Liu obtained his Bachelor's Degree in Pharmacy from the Department of Pharmacy of the Pharmaceutical University of Shenyang (September 1992 to July 1997) and a Ph.D. from the Department of Pharmaceutical Sciences at the University of Toronto (from September 2002 to October 2006). Furthermore, Mr. Liu is an author or co-author of several publications regarding medical and biological issues.

Mr. Dariusz Trzeciak – Vice President of the Supervisory Board

Mr. Dariusz Trzeciak has completed 4-year PhD studies at the Law and Administration Faculty of the University of Warsaw, Postgraduate MBA Studies at the Warsaw School of Economics and Law and Administration Faculty and History Faculty of the University of Warsaw. In the past, he held managerial and supervisory positions in many companies, including the function of the President of the Management Board of Towarzystwo Ubezpieczeń na Życie Polisa Życie S.A., Sferia S.A., IT Polpager S.A. At present, he holds the position of: a Member of the Management Board of Sferia S.A., a Member of the Management Board of Aero 2 Sp. z o.o. and Vice-Chairman of the Supervisory Board of Muzo FM Sp. z o.o. (formerly Radio PIN) and member of the Supervisory Board of Altalog Sp. Z o.o.. He is also a member of elected bodies in professional organizations and chambers of commerce.

Dr Ramesh Rajentheran - Vice President of the Supervisory Board

Dr Ramesh Rajentheran is the Founder & CEO of AlleleHealth Pte Ltd, Singapore since August 2018. Since 2015 to August 2018 Dr Ramesh Rajentheran was the Group Chief Financial Officer and Group Chief Operating Officer at Fullerton Health (FHC) in Singapore. From 2011 to 2015 Dr Ramesh Rajentheran was hired as the Managing Director, Head - Asian Healthcare Investment Banking at Barclays, Investment Banking Division, Singapore/Hong Kong. Between 2010 and 2011, Dr Ramesh Rajentheran was the Head of Markets & Equities and Senior Advisor to Executive Chairman at Hong Leong Group, Kuala Lumpur, Malaysia. Since 2009 to 2010 Dr Ramesh Rajentheran was working at Barclays Capital, London, UK as the Director- Global Healthcare Industry Specialist, Equities. From 2006 -2009 Dr Ramesh Rajentheran was the Executive Director- Global Healthcare Specialist Sales, Equities at Morgan Stanley, London, UK. In 2004, Dr Ramesh Rajentheran obtained MBA diploma in finance at London Business School and Bachelor's Degree in 1999 at Newcastle Medical School, Newcastle, UK.

Mr. Vaidyanathan Viswanath – Member of the Supervisory Board

Mr. Vaidyanathan Viswanath is a post-graduate in Pharmacology with about 3 decades experience in sales, marketing, business development and strategic planning in the pharmaceutical industry across Asia. His previous experience includes Serum Institute (Serono) and Astra in India both in sales and marketing, 8 years with Pharmacia in India and China. Mr. Vaidyanathan Viswanath was then the BD and Strategic Planning Director for Pfizer China and BD Director - Asia for Capsugel (Division of Pfizer) until 2011 based in Bangkok. Currently living in Beijing, Mr. Vaidyanathan Viswanath is an Independent Consultant for a number of pharma companies and in this role offers his expertise in the area of Strategic Marketing, Business Development, Marketing and Sales Effectiveness, Alliance Management, KOL & Advocacy development. With his deep understanding of the trends in the industry backed up by his strong networking capabilities, Mr. Vaidyanathan Viswanath envisions to act as a bridge for these companies to reach out to companies overseas and visa versa.

Mr. Ming-Tso Mark Chiang - Member of the Supervisory Board

Mr. Ming-Tso Mark Chiang received PhD degree in Computer Science in University of London and had more than five years of working experience as an analyst. Solid commercial excellence experience in MNC pharmaceutical since the end of 2009. This covers numerous sales and marketing initiatives including segmentation and targeting process, territory alignment, incentive scheme design, CRM system design, multichannel marketing roadmap design, reporting dashboards and training and coaching. Strong experience on business operation and cross functional collaboration.

Mr. Bo Qi - Member of the Supervisory Board

Mr. Bo Qi has over twenty-seven years of proven track record of achievement in major leading biopharmaceutical companies in US and China, with solid knowledge and experience in pharmaceutical drug lifecycle including process development, validation, technology transfer, manufacturing and regulatory filing. He worked on multiple world-wide approved recombinant protein/monoclonal antibody products, e.g. Aranesp (Amgen), Erbitux (ImClone) and Cyramza (Lilly) and Portrazza (Lilly).

Industrial experience– Genron corporation, CHINA/Vice President and Head of CMC, General Manager of Generon Beijing Plant (2015-Present) – Eli Lilly and Company (NJ), US/ Director of CMC Development (2008-2015) – ImClone System Inc., NJ, US/Director of Process Development (2002-2008) – Amgen Inc., CA, US /Associate Scientist of Process Development (1992-2002).

Education – M.Sc in Biochemistry, University of Minnesota, US (1988-1991) – B.Sc in Biochemistry, East China Univ. of Sci & Tech, China (1980-1984).

Mr. Gary He - Member of the Supervisory Board

Mr. Gary is the Vice President of CMC Global Compliance at Generon Corporation Ltd. since November 2016. From April 2004 to October 2016 he was an Associate Director at Eli Lilly & Company (US New Jersey) (served as a member of the Site Management Team, the Change Board, the Quality Board, and the Engineering Team to manage the site wide production and quality activities). From September 2001 to April 2004, he acted as a senior consultant at Bristol-Myers Squibb (US New Jersey). From April 1995 to August 2001 he was a senior engineer at Lockwood Greene Engineering (US New Jersey). From January of 1994 to January of 1995 he was a validation engineer at Qualis Inc. (US Iowa). From August 1984 to February 1990, he served as a project engineer/product supervisor at No. 3 Pharmaceutical Company in Shanghai. Mr. Gary He obtained his Bachelor's Degree in Biochemical Engineering from East China Technical Institute, Shanghai, P.R. China (from September 1980 to July 1984) and a Master's Degree in Chemical Engineering from Wayne State University, Michigan (from September 1990 to September 1993).